The analysis of the consumption level of antihypertensive drugs and statins in a retail pharmacy of the Samara Region in 2015–2020

Objective: to determine the compliance of antihypertensive drugs consumption with the trends of modern pharmacotherapy.

Material and methods. The analysis of the consumption level of antihypertensive drugs, their fixed combinations (FC), as well as statins in the retail sector of the pharmaceutical market of the Samara Region in 2015–2020 was carried out. The material of this retrospective study was information about the nomenclature and volume of drug sales in physical and monetary terms for the period under review in one of the retail pharmacies of the Samara Region. The traditional method of pharmacoepidemiological analysis aimed at studying the correctness, completeness and preferences of drug use in real practice is questionnaires for physicians and patients. The main antihypertensive drugs (diuretics, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, β-blockers) and their FC were selected for the analysis.

Results. Long-term use of medications aimed at reducing high blood pressure and hypercholesterolemia is seen as an effective strategy for reducing cardiovascular complications and mortality in both primary and secondary prevention. The analysis of sales of basic cardiological drugs in the pharmacy network segment of the Samara Region in 5-year dynamics showed that the consumption of hypotensive drugs and statins makes up 4.72% of the total item sales, with prevalence of angiotensin-converting enzyme inhibitors (28.0%) and β-blockers (23.5%), with insufficient consumption of FC (23.7%), extremely low sales of statins (7.58%).

Conclusion. The structure of the studied segment of the pharmaceutical market is conservative with insufficient positive dynamics in the consumption of effective modern drugs and their FC. 

1. Oparil S., Acelajado M.C., Bakris G.L., et al. Hypertension. Nat Rev Dis Primer. 2018; 4: 18014. https://doi.org/10.1038/nrdp.2018.14.

2. Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Hypertension. 2018; 71 (6): 1269–324. https://doi.org/10.1161/HYP.0000000000000066.

3. Williams B., Mancia G., Spiering W., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39 (33): 3021–104. https://doi.org/10.1093/eurheartj/ehy339.

4. Roth G.A., Johnson C., Abajobir A., et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70 (1): 1–25. https://doi.org/10.1016/j.jacc.2017.04.052.

5. Leonova M.V., Steinberg L.L., Belousov Yu.B., et al. Results of pharmacoepidemiologic study of arterial hypertension Pifagor IV: physicians compliance. Russian Journal of Cardiology. 2015; 1: 59–66 (in Russ.). https://doi.org/10.15829/1560-4071-2015-1-59-66.

6. Johansen M.E., Niforatos J.D., Sussman J.B. The ecology of antihypertensives in the United States, 1997–2017. J Gen Intern Med. 2021; 36 (3): 699–704. https://doi.org/10.1007/s11606-020-06214-1.

7. Overview of the pharmacy segment of medicines for the first quarter of 2020. Moscow pharmacies. Pharmaceutical newspaper. Available at: https://mosapteki.ru/material/obzor-aptechnogo-segmenta-lp-zakvartal-2020-g-12963 (in Russ.) (accessed 15.01.2021).

8. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370 (9590): 829–40. https://doi.org/10.1016/S0140-6736(07)61303-8.

9. Shalnova S.A., Deev A.D., Metelskaya V.A., et al. Awareness and treatment specifics of statin therapy in persons with various cardiovasular risk: the study ESSE-RF. Cardiovascular Therapy and Prevention. 2016; 15 (4): 29–37 (in Russ.). https://doi.org/10.15829/1728-8800-2016-4-29-37.

10. The top 300 of 2021. Provided by the ClinCalc DrugStats Database. Available at: https://clincalc.com/DrugStats/Top300Drugs.aspx (accessed 15.01.2021).

11. Khaisheva L.A., Glova S.E., Suroedov V.A., et al. Evaluation of drug therapy and adherence to it in patients after acute coronary syndrome in real clinical practice (results of one year observation). Rational Pharmacotherapy in Cardiology. 2018; 14 (6): 852–7 (in Russ.). https://doi.org/10.20996/1819-6446-2018-14-6-852-857.

12. Yezhov M.V., Lazareva N.V., Sagaidak O.V., et al. Prevalence of dyslipidemia and statins use in acute coronary syndrome (Federal Register of Acute Coronary Syndrome). Journal of Atherosclerosis and Dyslipidemias. 2018; 1: 47–58 (in Russ.).

13. Bubnova M.G., Aronov D.M., Deev A.D. Statin therapy in real clinical practice in elderly patients with hyperlipidemia and coronary heart disease. The Russian program EFFORT. Journal of Atherosclerosis and Dyslipidemias. 2018; 1: 5–16 (in Russ.).